USPTO upholds ten amended claims of SANUWAVE's '119 patent

SANUWAVE Health, Inc. (OTCBB: SNWV) (www.sanuwave.com), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in regenerative medicine, today reported that the U.S. Patent and Trademark Office (USPTO) issued a reexamination certificate upholding ten amended claims of SANUWAVE's U.S. Patent No. 6,080,119 following a third party's ex parte reexamination request. This innovative device and method patent describes the Company's invention of effective catalyst concentrations to produce optimal medical shock waves.

“We are very pleased that the reexamination proceedings have been brought to a successful conclusion. We believe that the issuance of this reexamination certificate confirms SANUWAVE's technological leadership in medical shock wave technology”

The USPTO confirmed that SANUWAVE was entitled to amend the patent claims to the full range of catalyst concentrations disclosed in the '119 patent as a continuing novel innovation in medical shock wave treatment.

"We are very pleased that the reexamination proceedings have been brought to a successful conclusion. We believe that the issuance of this reexamination certificate confirms SANUWAVE's technological leadership in medical shock wave technology," said Christopher M. Cashman, President and CEO of SANUWAVE. "This patent recognizes our technology as a novel innovation, allowing us to aggressively defend our intellectual property. The strength of this intellectual property, combined with compelling clinical outcomes and favorable market dynamics, allow us to continually advance our PACE^® technology across multiple market verticals, with a near-term focus on wound healing and orthopedics."